Aptose Biosciences Inc. (“Aptose” or the “Company”) is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company’s executive offices are located in San Diego, California and its head office is located in Toronto, Canada.

 

Aptose has clinical-stage programs and a program that is discovery-stage and partnered with another company. (“CG-), Aptose’s pan-FMS-like tyrosine kinase / pan-Bruton’s tyrosine kinase inhibitor, is currently enrolling patients in a Phase multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG- in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). Aptose plans to seek allowance from the FDA to move into patient populations that include relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in a separate Phase trial. APTO- Aptose’s program, is a small molecule MYC inhibitor and is currently enrolling patients in a Phase clinical trial for the treatment of patients with R/R blood cancers, including AML and high-risk Myelodysplastic Syndrome.